Etomidate Versus Ketamine for Emergency Endotracheal Intubation: a Prospective Randomized Clinical Trial
| Status: | Recruiting |
|---|---|
| Conditions: | Cardiology, Hospital, Pulmonary |
| Therapuetic Areas: | Cardiology / Vascular Diseases, Pulmonary / Respiratory Diseases, Other |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 1/19/2019 |
| Start Date: | June 6, 2016 |
| End Date: | January 2023 |
| Contact: | Gerald Matchett, MD |
| Email: | info@evktrial.org |
| Phone: | 214-648-6400 |
Patients who are having problems breathing sometimes require placement of a breathing tube in
their mouth and windpipe. The purpose of this breathing tube is to save the patient's life.
It is common to give the patient a medication to sedate him or her before the breathing tube
is placed. For patients who are gravely ill two medications are commonly used: etomidate or
ketamine. Both medications have risks and benefits. Researchers at UT-Southwestern Medical
Center and Parkland Memorial Hospital would like to do a study to figure out which one is
better for our patients.
their mouth and windpipe. The purpose of this breathing tube is to save the patient's life.
It is common to give the patient a medication to sedate him or her before the breathing tube
is placed. For patients who are gravely ill two medications are commonly used: etomidate or
ketamine. Both medications have risks and benefits. Researchers at UT-Southwestern Medical
Center and Parkland Memorial Hospital would like to do a study to figure out which one is
better for our patients.
Critically ill individuals who require emergency endotracheal intubation (placement of a
breathing tube in the patient's mouth) usually require sedation or anesthesia to make this
process tolerable. There are several medication choices for anesthesia, including medications
like etomidate, ketamine and propofol. Of these, etomidate and ketamine are frequently used
for critically ill patients because they have minimal effects on the patient's vital signs
(blood pressure and heart rate). Both etomidate and ketamine are standard-of-care
medications, locally and nationally, and both are frequently used to sedate a patient for
this procedure. Both etomidate and ketamine have potential side effects. One of the potential
side effects of etomidate is suppression of adrenal gland function. It is not known if this
affects patients' outcomes in significant ways. One of the potential side effects of ketamine
is a slight increase in patients' heart rates. It is not known if this affects patients'
outcomes in significant ways.
The EvK Trial will be conducted at Parkland Memorial Hospital by investigators in the
Departments of Anesthesiology, Emergency Medicine, Medicine / Critical Care Medicine,
Surgery, and Pharmacy. The study will randomize critically ill patients who require emergency
endotracheal intubation to one of two groups: Etomidate or Ketamine. We will observe the
patients' outcomes. The only study intervention involves randomizing individual patients to
one medication or the other. All study follow-up beyond that point is done by review of
medical records.
Because of the nature of this study - an emergency procedure on a critically ill patient -
the study will require institutional review board permission not to obtain written informed
consent from the patient prior to randomization of study drug for administration for
endotracheal tube placement. Prior to enrollment of patients the study team will carry out a
comprehensive Community Consultation Plan, which is designed to inform the community about
the research study. This is in accordance with rules set forth by the U.S. Food and Drug
Administration (FDA 21 CFR 50.24).
breathing tube in the patient's mouth) usually require sedation or anesthesia to make this
process tolerable. There are several medication choices for anesthesia, including medications
like etomidate, ketamine and propofol. Of these, etomidate and ketamine are frequently used
for critically ill patients because they have minimal effects on the patient's vital signs
(blood pressure and heart rate). Both etomidate and ketamine are standard-of-care
medications, locally and nationally, and both are frequently used to sedate a patient for
this procedure. Both etomidate and ketamine have potential side effects. One of the potential
side effects of etomidate is suppression of adrenal gland function. It is not known if this
affects patients' outcomes in significant ways. One of the potential side effects of ketamine
is a slight increase in patients' heart rates. It is not known if this affects patients'
outcomes in significant ways.
The EvK Trial will be conducted at Parkland Memorial Hospital by investigators in the
Departments of Anesthesiology, Emergency Medicine, Medicine / Critical Care Medicine,
Surgery, and Pharmacy. The study will randomize critically ill patients who require emergency
endotracheal intubation to one of two groups: Etomidate or Ketamine. We will observe the
patients' outcomes. The only study intervention involves randomizing individual patients to
one medication or the other. All study follow-up beyond that point is done by review of
medical records.
Because of the nature of this study - an emergency procedure on a critically ill patient -
the study will require institutional review board permission not to obtain written informed
consent from the patient prior to randomization of study drug for administration for
endotracheal tube placement. Prior to enrollment of patients the study team will carry out a
comprehensive Community Consultation Plan, which is designed to inform the community about
the research study. This is in accordance with rules set forth by the U.S. Food and Drug
Administration (FDA 21 CFR 50.24).
Inclusion Criteria:
- Adult patient (male or female) requiring emergency endotracheal intubation.
Exclusion Criteria:
- Children (<18 years old).
- Women who are known to be pregnant.
- Any patient who has been previously randomized in the EvK Trial.
- Patients who require endotracheal intubation without sedative medication. For example,
patients in full cardiac arrest.
- Patients with a known allergy to ketamine or etomidate.
- Any individual wearing a MedAlert bracelet indicating that he/she has formally opted
out of the EvK Trial.
We found this trial at
1
site
Dallas, Texas 75390
Principal Investigator: Gerald Matchett, M.D.
Phone: 214-590-6723
Click here to add this to my saved trials
